Rieke Fischer

2.1k total citations
33 papers, 675 citations indexed

About

Rieke Fischer is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Rieke Fischer has authored 33 papers receiving a total of 675 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 16 papers in Oncology and 10 papers in Molecular Biology. Recurrent topics in Rieke Fischer's work include Lung Cancer Treatments and Mutations (15 papers), Cancer Genomics and Diagnostics (8 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Rieke Fischer is often cited by papers focused on Lung Cancer Treatments and Mutations (15 papers), Cancer Genomics and Diagnostics (8 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Rieke Fischer collaborates with scholars based in Germany, United States and Spain. Rieke Fischer's co-authors include Andreas H. Scheel, Jürgen Wolf, Lukas C. Heukamp, Hans‐Ulrich Schildhaus, Wilko Weichert, Simone Reu, Korinna Jöhrens, Peter Schirmacher, Arne Warth and Manfred Dietel and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Journal of Leukocyte Biology.

In The Last Decade

Rieke Fischer

25 papers receiving 657 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rieke Fischer Germany 9 503 270 151 122 79 33 675
Ignacio Matos Spain 17 521 1.0× 206 0.8× 145 1.0× 89 0.7× 89 1.1× 57 818
Pradeep Thanigaimani United States 7 503 1.0× 175 0.6× 110 0.7× 56 0.5× 129 1.6× 11 669
Bhumsuk Keam South Korea 9 312 0.6× 134 0.5× 122 0.8× 56 0.5× 247 3.1× 17 568
A Bardier France 9 415 0.8× 119 0.4× 207 1.4× 103 0.8× 32 0.4× 28 648
Angel Qin United States 12 343 0.7× 201 0.7× 94 0.6× 122 1.0× 22 0.3× 33 561
Junzhou Wu China 15 321 0.6× 176 0.7× 94 0.6× 133 1.1× 30 0.4× 30 645
Shafei Wu China 16 440 0.9× 338 1.3× 52 0.3× 165 1.4× 37 0.5× 59 720
Hidenori Mizugaki Japan 14 400 0.8× 231 0.9× 72 0.5× 92 0.8× 64 0.8× 40 710
Kuniko Sunami Japan 16 320 0.6× 297 1.1× 42 0.3× 196 1.6× 20 0.3× 47 638
Samuel Suzuki United States 9 228 0.5× 130 0.5× 39 0.3× 102 0.8× 113 1.4× 22 460

Countries citing papers authored by Rieke Fischer

Since Specialization
Citations

This map shows the geographic impact of Rieke Fischer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rieke Fischer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rieke Fischer more than expected).

Fields of papers citing papers by Rieke Fischer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rieke Fischer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rieke Fischer. The network helps show where Rieke Fischer may publish in the future.

Co-authorship network of co-authors of Rieke Fischer

This figure shows the co-authorship network connecting the top 25 collaborators of Rieke Fischer. A scholar is included among the top collaborators of Rieke Fischer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rieke Fischer. Rieke Fischer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Riedel, Richard, Lucia Nogová, Sebastian Michels, et al.. (2025). MET-Driven Resistance to Sotorasib in KRAS G12C–Mutant NSCLC and Response to Combined KRAS and MET Inhibition. JTO Clinical and Research Reports. 7(3). 100925–100925.
2.
Fischer, Rieke, Julie George, Hans Anton Schloesser, et al.. (2024). BIOLUMA: A phase II trial of nivolumab and ipilimumab in lung cancer—Results from the SCLC TMBhigh cohort.. Journal of Clinical Oncology. 42(16_suppl). 8099–8099. 1 indexed citations
3.
Kuempers, Christiane, Sebastian Marwitz, Andreas H. Scheel, et al.. (2024). Upregulation and epigenetic modification of the creatine transporter SLC6A8 in non-small cell lung cancer.. PubMed. 39(7). 867–876.
4.
Fassunke, Jana, Michael Püsken, Elke Binot, et al.. (2023). Durable Response With Sequential Tyrosine Kinase Inhibitor Treatment in a Patient With ROS1 Fusion–Positive Pancreatic Adenocarcinoma: A Case Report. JCO Precision Oncology. 7(7). e2200467–e2200467. 2 indexed citations
5.
Riedel, Richard, Sebastian Michels, Carina Heydt, et al.. (2019). Acquired KRAS mutation and loss of low-level MET amplification after durable response to crizotinib in a patient with lung adenocarcinoma. Lung Cancer. 133. 20–22. 2 indexed citations
6.
Abdulla, Diana S.Y., Matthias Scheffler, Carsten Kobe, et al.. (2019). Overcoming acquired osimertinib-resistance in EGFR-mutant advanced non-small lung cancer mediated by activating BRAF V600E mutation.. Journal of Clinical Oncology. 37(15_suppl). e20682–e20682. 2 indexed citations
7.
Bersanelli, Melissa, Roberto Iacovelli, Sebastiano Buti, et al.. (2019). Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?. European Urology Oncology. 4(2). 274–281. 8 indexed citations
8.
Nogová, Lucia, Florian Malchers, Axel M. Hillmer, et al.. (2018). P1.01-72 FIND Trial: A Phase II Study to Evaluate the Efficacy of the FGFR-Inhibitor Erdafitinib in FGFR-Mutated and -Translocated Squamous NSCLC. Journal of Thoracic Oncology. 13(10). S490–S490. 1 indexed citations
9.
Michels, Sebastian, Matthias Scheffler, Dennis Plenker, et al.. (2018). Loss of G2032R Resistance Mutation Upon Chemotherapy Treatment Enables Successful Crizotinib Rechallenge in a Patient With ROS1-Rearranged NSCLC. JCO Precision Oncology. 2(2). 1–6. 3 indexed citations
10.
Riedel, Richard, Anna Kron, Sebastian Michels, et al.. (2017). Impact of next generation TKI and co-occurring mutations in ALK-positive NSCLC patients: Results of the Network Genomic Medicine. Annals of Oncology. 28. v474–v474.
11.
Kron, Anna, Richard Riedel, Sebastian Michels, et al.. (2017). Impact of co-occurring genomic alterations on overall survival of BRAF V600E and non-V600E mutated NSCLC patients: Results of the Network Genomic Medicine. Annals of Oncology. 28. v461–v462. 6 indexed citations
12.
Michels, Sebastian, Andreas H. Scheel, Thomas Wündisch, et al.. (2017). ALK G1269A mutation as a potential mechanism of acquired resistance to crizotinib in an ALK-rearranged inflammatory myofibroblastic tumor. npj Precision Oncology. 1(1). 4–4. 30 indexed citations
13.
Maass, Nicolaì, et al.. (2016). Phototheranostics immunoconjugates to detect eliminate triple negative breast cancer cells. RWTH Publications (RWTH Aachen). 1 indexed citations
14.
Scheel, Andreas H., Manfred Dietel, Lukas C. Heukamp, et al.. (2016). Prädiktive PD-L1-Immunhistochemie beim nichtkleinzelligen Bronchialkarzinom. Aktueller Stand und Erfahrungen der ersten deutschen Harmonisierungsstudie. Der Pathologe. 37. 17 indexed citations
15.
Scheel, Andreas H., Manfred Dietel, Lukas C. Heukamp, et al.. (2016). Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Modern Pathology. 29(10). 1165–1172. 268 indexed citations
16.
Scheel, Andreas H., Sascha Ansén, Anne M. Schultheis, et al.. (2016). PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations. OncoImmunology. 5(5). e1131379–e1131379. 89 indexed citations
17.
Scheel, Andreas H., Manfred Dietel, Lukas C. Heukamp, et al.. (2016). Prädiktive PD-L1-Immunhistochemie beim nichtkleinzelligen Bronchialkarzinom. Der Pathologe. 37(6). 557–567. 31 indexed citations
18.
Loprinzi, Charles L., et al.. (1998). Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes.. PubMed. 82(9). 1784–8. 108 indexed citations
19.
Diehl, Volker, Rieke Fischer, J. Thiele, et al.. (1995). The impact of interferon versus busulfan therapy on the reticulin stain-measured fibrosis in CML ? a comparative morphometric study on sequential trephine biopsies. Annals of Hematology. 70(3). 121–128. 5 indexed citations
20.
Nolte, M., Martin Werner, R von Wasielewski, et al.. (1995). The bcl-2/JH gene rearrangement is undetectable in Hodgkin's lymphomas: results from the German Hodgkin trial. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 426(1). 37–41. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ignacio Matos Breakdown of academic impact, for papers by Pradeep Thanigaimani Breakdown of academic impact, for papers by Bhumsuk Keam Breakdown of academic impact, for papers by A Bardier Breakdown of academic impact, for papers by Angel Qin Breakdown of academic impact, for papers by Junzhou Wu Breakdown of academic impact, for papers by Shafei Wu Breakdown of academic impact, for papers by Hidenori Mizugaki Breakdown of academic impact, for papers by Kuniko Sunami Breakdown of academic impact, for papers by Samuel Suzuki
Rankless by CCL
2026